Stock Market

Allogene Therapeutics Cancer Program Remains on Track in 2026

By Bullbit Editorial · March 29, 2026

WhatAllogene Therapeutics' lead cancer program remains on track for 2026.
WhyThe company cites ongoing clinical trials and positive data as key factors.
SignalA strong pipeline of cancer treatments is expected to drive growth in the coming years.
TargetAllogene aims to submit a Biologics License Application (BLA) for its lead program by the end of 2026.
RiskRegulatory hurdles and competition from established players in the cancer treatment market remain a concern.